medigraphic.com
ISSN 0188-2198 (Print)

2005, Number 4

<< Back Next >>

Rev Mex Cardiol 2005; 16 (4)

Effectiveness and safety of two formulations of slow release fenproporex as management of obesity

Morín ZR, Ponce LML, Lonngi VS, Alcaraz OR, Lonngi VG

Language: Spanish
References: 28
Page: 146-154
PDF size: 101.76 Kb.


ABSTRACT

Background: Obesity is a health problem that often requires drug therapy as part of their management. Objective: Actualize the data about effectiveness and safety of fenproporex in a slow release formulation as part of the management of obesity. Patients and procedure: Ninety obese (BMI 3 30) adult patients were treated during six months plus one withdrawal month. Participants were randomly assigned to one of three groups: placebo (P), slow release fenproporex 20 mg/day (LLFPX) and slow release 20 mg + diazepam 6 mg (LLFPX+D). Hypocaloric diet and a 30 minutes walk every day were also indicated. Medical history was done at day 0 and at 30 days intervals. Laboratory tests were performed on days 0, 90, 180 y 210. A statistical difference of p ‹ 0.05 was considered as significative. Results: All groups lose weigh and reduce their BMI. However, these changes were earlier and more pronounced in the LLFPX and LLFPX+D groups. Reduction was observed mainly in body fat and correlate with the waist circumference reduction. The percentage of body weight reduced at day 180 was 5.3% in the P group, and 8.8% and 12.2% in the LLFPX and LLFPX+D groups respectively (p ‹ 0.05 vs basal). Reduction in the blood pressure and improvement in blood lipids was also noted. Adverse events were mild, observed mainly in the first three months of therapy and no withdrawal was required for this reason. Conclusion: Because their efficacy and safety profile, slow release fenproporex could be considered as one of the drug options in the management of obesity.


REFERENCES

  2. Informe conjunto de expertos de la OMS y la FAO sobre régimen alimentario, nutrición y prevención de enfermedades crónicas. 13ª Reunión Interamericana a Nivel Ministerial en Salud y Agricultura. RIMSA 13/20. 2003.

  3. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar C, Cravioto P, López P, Hernández M, Tapia R, Sepúlveda J. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Cuernavaca, Morelos, México. Instituto Nacional de Salud Pública, 2003.

  4. The Practical guide to the identification, evaluation and treatment of overweight and obesity in adults. Bethesda, Maryland: NIH; Publication number 00-4084 2000.

  5. Rivera-Domarco, Barquera S y cols. Análisis de los ENIGH 1984-1988. Conferencia sobre transición epidemiológica y nutricia. Bellagio-Italia 2001.

  6. Rivera-Domarco, Barquera S et al. Análisis de la Encuesta Nacional de Ingreso y Gasto en los Hogares (ENIGH), INEGI. Public Health Nutrition 2002; 5: 113-22.

  7. Hernández B, de Haene J, Barquera S, Monterrubio E, Rivera J, Shamah T, Sepúlveda J, Haas J, Campirano F. Factores Asociados con la actividad física en mujeres mexicanas en edad reproductiva. Rev Panam Salud Pública 2003; 14: 235-245.

  8. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60: 647-57.

  9. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacolotherapy in the management of obesity. JAMA 1996; 276: 1907-1915.

  10. Atkinson R, Van Hubbard S. Report on the NIH workshop on pharmacologic treatment of obesity. Am J Clin Nutr 1994; 60: 153-6.

  11. Hensrud DD. Farmacoterapia para la obesidad. Clin Med Norteamérica 2000; 2: 455-466.

  12. Silverstone T. Appetite suppressants. Drugs 1992; 43: 820-36.

  13. Morín R, Lonngi G, Alcaraz R, Rosas D. Comparación de dos formulaciones de d-norpseudoefedrina y placebo en pacientes obesos tratados durante seis meses. Med Int (Mex) 2001; 17: 260-71.

  14. Castañeda G, Caillke G, du Souich P. Influence of drug formulation on drug concentration-effect relationships. Clin Pharmacokinet 1994; 26: 135-43.

  15. Billings D, Koch G. The application of he principle of intention-to-treat to the analysis of clinical trials. Drug Informat J 1991; 25: 411-24.

  16. Warembourg H, Jaillard J. Expérimentation clinique du fenproporex dans le traitement des obesites. Lille Medical 1968; 13: 273-6.

  17. Soulairac A. Etude electroencephalographique et statokinesimetrique du perphoxene chez l’homme. Therapeutique 1971; 47: 365-9.

  18. Luquero F. Tratamiento de la obesidad con un nuevo fármaco lipolítico y anorexigénico: el fenproporex. Rev Esp Ap Resp 1971; 34: 91-8.

  19. Faivre G, Dodinot B, Hua G. Traitement de l’obesite chez les cardiaques experimentation d’un nouvel anorexigene. La Vie Medicale 1969; 2: 730-4.

  20. Munro JF. Clinical aspects of the treatment of obesity by drugs: a review. Int J Obesity 1979; 3: 171-80.

  21. Galloway S, Fuqua D, Munro JF. The current status of antiobesity drugs. Postgraduate Medical Journal 1984; 60 (Suppl. 3):S19-S26.

  22. Scoville BA. Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgement. In: Bray GA editor. Obesity in perspective. DHEW Publ. No. (NIH) 75-708., Bethesda (MD): National Institutes of Health, 1975: 441-3.

  23. Rall T, Schleifer L. Fármacos efectivos en el tratamiento de la epilepsia. Bases Farmacológicas de Terapéutica. Good y Guillman, 8a Ed. Ed. Panamericana. 1991: 433-457.

  24. Bray G, Ryan D, Gordon D, Heidigssfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4: 263-70.

  25. Davidson MH et al. Weigh control and risk factor reduction in obese subjects treated for 2 years with Orlistat. JAMA 1999; 281: 235-242.

  26. Silva O, Yonamine M, Antunes C, Greve J, Midio A. Fenproporex abuse by truck drivers in Brazil. www.tiaft.org/tiaft98/thu/p/t_p_32.html

  27. Kinell HG. European Withdrawal of appetite suppressants. Obesity reviews. 2003; 4: 79-81.

  28. Rossner S. Long-term intervention strategies in obesity treatment. Int J Obes Relat Metab Disord 1995; 19(Suppl. 7): S29-S33.




2020     |     www.medigraphic.com